Transitional Period
Federal departments are moving their web content to Canada.ca. As a part of that process, proactive disclosure reports will become available through the Open Government portal. During this transition, if a proactive disclosure report from a specific department is not yet available on the Open Government portal please refer to Proactive disclosure by department or agency where a copy can be found. For any questions on this issue, please contact us at open-ouvert@tbs-sct.gc.ca .
About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests previously made to the Government of Canada. If you find a summary of interest, you can request a copy of the records at no cost. For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator.
Enter keywords (e.g. institution, topic, field of interest, etc.)
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Year
Month
Found 219 record(s)
Req # A-2015-000173
Since 2007, all documentation pertaining to the bioequivalance and drug submission requirements for subsequent entry long-acting anti-cholinergic respiratory products, including but not limited to subsequent-entry tiotropium containing products.Organization: Health Canada
September 2019
Req # A-2016-000063
From January 1, 1997 to April 15, 2016: Exchanges between Health Canada's Market Health Products Directorate and Purdue Pharma promotional practices involving marketing of Oxycontin and OxyNeo concerning potential marketing tactics.Organization: Health Canada
September 2019
Req # A-2016-000306
Reviewer’s comments and correspondence pertaining to the safety, efficacy, labelling and specifically the approval of the transvaginal mesh products manufactured by Covidien Inc. and Tyco, associated Surgipro Mesh and Parietene Mesh.Organization: Health Canada
September 2019
Req # A-2016-000652
Internal Strategic Policy Branch (SPB) correspondence, EX level and higher, relating to the constitutionality and Carter-compliance of C-14's reasonable foreseeability clause, from January 1, 2016 to September 28, 2016.Organization: Health Canada
September 2019
Req # A-2016-000690
Copies of all Health Canada materials/records related to plain packaging for tobacco products for the month of August 2016.Organization: Health Canada
September 2019
Req # A-2016-001048
Briefing documents provided to Canada's delegation to the World Health Organization (WHO) Seventh session of the Conference of the Parties (COP7) held in Delhi, India, starting on November 7, 2016.Organization: Health Canada
September 2019
Req # A-2016-001513
A list of all received emails from Denis Choiniere between October 1, 2016 to December 31, 2016.Organization: Health Canada
September 2019
Req # A-2016-001514
Monthly internet browsing history for Denis Choiniere from January 1, 2016 to December 31, 2016.Organization: Health Canada
September 2019
Req # A-2017-000561
Since January 1, 2015, all risk assessment reports for Consumer Product Safety related to the following item: Carbon Monoxide Alarm.Organization: Health Canada
September 2019
Req # A-2017-001093
Correspondence since June 1, 2017 between the Minister of Health and/or Health Canada or any other entity in the federal health portfolio regarding extra billing/user fees charged/double billing by doctors.Organization: Health Canada
September 2019